SCHEMBL20116476

SCHEMBL20116476

CC(C)n1ncc2ccc(-c3noc(C4CCN(C(=O)c5ccsc5Cl)CC4)n3)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.45
LMNA P02545 5/20 0.45
TSHR P16473 5/20 0.45
HTT P42858 5/20 0.44
ALDH1A1 P00352 5/20 0.43
NPSR1 Q6W5P4 2/20 0.41
SMO Q99835 1/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22357920 0.89 SMN1; SMN2 (0.45) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL22357857 0.87 HSD11B1 (0.54) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL20117067 0.86 SMN1; SMN2 (0.45) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL22358359 0.86 LMNA (0.54) SMN1; SMN2LMNATSHRHTTNPSR1
SCHEMBL20116479 0.85 LMNA (0.57) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL20116433 0.85 ALDH1A1 (0.51) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL20116401 0.85 SMN1; SMN2 (0.43) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL22358006 0.84 NPSR1 (0.47) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL22357915 0.84 SMN1; SMN2 (0.56) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL22357882 0.84 SMN1; SMN2 (0.54) SMN1; SMN2LMNATSHRHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMN1; SMN2 13/4885LMNA 1966/4885TSHR 4679/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMN1; SMN2 13/4885LMNA 1966/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.